Published in Physician Law Weekly, August 18th, 2004
The presentations took place at the 9th International Conference on Alzheimer's Disease (ICAD) in Philadelphia.
The first study presented by Dr. Nicolas Sergeant from INSERM in France entitled "Amino-truncated A-beta 42 species as early diagnostic and etiological biomarkers of Alzheimer disease" described using a SELDI immunoassay to evaluate the presence of N-terminally truncated Abeta42 peptides in patient cerebrospinal fluid (CSF).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.